RedHill Biopharma (RDHL) Cash from Investing Activities (2012 - 2021)

RedHill Biopharma (RDHL) has 9 years of Cash from Investing Activities data on file, last reported at -$3.5 million in Q2 2021.

• On a quarterly basis, Cash from Investing Activities rose 92.97% year-over-year to -$3.5 million in Q2 2021; TTM through Jun 2021 was -$61.6 million, a 19.69% increase from a year earlier, with the FY2025 full-year figure at -$5000.0, up 44.44% from the prior year.
• Cash from Investing Activities for Q2 2021 stood at -$3.5 million, up from -$49.8 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for RDHL reached as high as -$3.4 million in Q2 2019 and fell as low as -$49.8 million in Q2 2020.
• Historically, Cash from Investing Activities has averaged -$16.0 million across 4 years, with a median of -$4.9 million in 2017.
• Across the five-year window, Cash from Investing Activities tumbled 1368.88% in 2020 and soared 92.97% in 2021, its largest moves.
• Year by year, Cash from Investing Activities stood at -$4.9 million in 2017, then jumped by 30.4% to -$3.4 million in 2019, then tumbled by 1368.88% to -$49.8 million in 2020, then surged by 92.97% to -$3.5 million in 2021.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$3.5 million in Q2 2021, -$49.8 million in Q2 2020, and -$3.4 million in Q2 2019.